PT-141+
What is PT-141+
PT-141+, also known by its clinical name Bremelanotide, is a synthetic peptide derived from Melanotan II, a compound originally developed for skin tanning research. Unlike most peptides that work through the vascular system, PT-141+ works directly through the central nervous system, making it unique among peptides used for sexual health. PT-141+ is a melanocortin receptor agonist, meaning it activates specific receptors in the brain associated with sexual arousal and desire. It is one of the few compounds studied specifically for its ability to address low libido and sexual dysfunction in both men and women. In 2019, the FDA approved a version of Bremelanotide under the brand name Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women, making it one of the only FDA-approved treatments for low sexual desire in women. Unlike medications that work by increasing blood flow, PT-141+ addresses sexual dysfunction at the neurological level, targeting desire and arousal rather than physical response alone.
History & Discovery
The story of PT-141+ begins not with sexual health research, but with skin pigmentation. In the 1980s, researchers at the University of Arizona began studying alpha-melanocyte stimulating hormone (α-MSH), a naturally occurring peptide that regulates skin pigmentation. Their goal was to develop a compound that could stimulate tanning without UV exposure, potentially reducing skin cancer risk. This research led to the development of Melanotan I and later Melanotan II in the early 1990s. During clinical trials of Melanotan II, researchers made an unexpected discovery, male participants were experiencing spontaneous erections as a side effect. This observation shifted the direction of research significantly. Scientists recognized that Melanotan II was activating melanocortin receptors in the brain that were linked to sexual arousal. This led to the development of PT-141+, a stripped-down analogue of Melanotan II designed specifically to target sexual function without the tanning effects. Clinical development of PT-141+ progressed through the 1990s and 2000s under the pharmaceutical company Palatin Technologies. After years of clinical trials evaluating its safety and efficacy in both men and women, the FDA approved Bremelanotide (PT-141+) in June 2019 under the brand name Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. It remains one of the most studied peptides in the field of sexual health and continues to be researched for broader applications in both men and women.
How it Works
PT-141+ is a melanocortin receptor agonist, specifically activating melanocortin receptors MC3R and MC4R in the brain. These receptors are located in areas associated with sexual arousal, motivation, and desire. When activated, they trigger neurological pathways that increase sexual desire and arousal from the brain down. This distinction is important:
— Most erectile dysfunction medications work by increasing blood flow to sexual organs. They address the physical response but not the underlying desire.
— PT-141+ works upstream, at the level of the brain, addressing the neurological component of sexual desire directly.
​
This is why PT-141+ has shown effectiveness in both men and women, and why it has been studied for cases where traditional treatments have failed. It does not rely on sexual stimulation to work, instead, it activates the brain's own arousal pathways to generate desire naturally. The effects typically begin within 45 minutes to 1 hour and can last several hours, making it one of the longer-acting options in its category.
Safety & Considerations
PT-141+ has been studied extensively in clinical trials and is generally well-tolerated. The FDA approved version, Vyleesi, provides a solid safety reference point. That said, the following side effects have been documented in clinical studies:
— Nausea is the most commonly reported side effect, occurring in a significant portion of clinical trial participants
— Flushing and warmth, particularly in the face, neck, and chest
— Transient increases in blood pressure following administration, typically resolving within 12 hours
— Headache reported in some users
— Fatigue or tiredness following use
— Hyperpigmentation (darkening of the skin, face, or gums) with repeated use over time
— Injection site reactions in clinical trial participants using injectable forms
​
Who should use caution or avoid PT-141+
— Not recommended during pregnancy or breastfeeding
— Those with cardiovascular disease or uncontrolled high blood pressure should consult their healthcare provider before use due to the transient blood pressure increase associated with PT-141
— Not recommended for use with medications that slow heart rate, as PT-141 can temporarily affect cardiovascular function
— Those with a history of hyperpigmentation disorders should use with caution
— If you have an existing health condition or are currently on medication, consult your healthcare provider before starting
​
If any adverse reactions occur, discontinue use immediately.
​
Sources
1. Molinoff, P.B. et al. (2003). PT-141: A melanocortin agonist for the treatment of sexual dysfunction. Annals of the New York Academy of Sciences, 994, 96–102. https://pubmed.ncbi.nlm.nih.gov/12851301/
​
2. Kingsberg, S.A. et al. (2019). Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstetrics & Gynecology, 134(5), 899–908. https://pubmed.ncbi.nlm.nih.gov/31599840/
​
3. Simon, J.A. et al. (2019). Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. Obstetrics & Gynecology, 134(5), 909–917. https://pubmed.ncbi.nlm.nih.gov/31599847/
​
4. Van der Ploeg, L.H. et al. (2002). A role for the melanocortin 4 receptor in sexual function. Proceedings of the National Academy of Sciences, 99(17), 11381–11386. https://pubmed.ncbi.nlm.nih.gov/12165565/
​
5. Wessells, H. et al. (2000). Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. Journal of Urology, 160(2), 389–393. https://pubmed.ncbi.nlm.nih.gov/10411041/
​
6. Dhillon, S. & Keam, S.J. (2019). Bremelanotide: First Approval. Drugs, 79, 1599–1606. https://pubmed.ncbi.nlm.nih.gov/31429064/
​
7. LiverTox. (2021). Bremelanotide. National Institute of Diabetes and Digestive and Kidney Diseases, National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK573221/
The following information is based on published third-party research and is provided for educational purposes only. It does not represent the effects of any Resilience EQ product. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.